Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Investing Cash Flow

Investing Cash Flow at other companies

AbbVie logo
AbbVieABBV
-$574M+21.9%
Bausch + Lomb logo
Bausch + LombBLCO
-$87M+3.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$4.66M-141%
HRO
HarrowHROW
-$18.2M-8,486%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$75.1M+55.4%
Schering-Plough logo
Schering-PloughSGP
-$1.67M-916%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.87B+63.9%
Enterprise value$2.75B+59.6%
P/S4.7×-1.2×

Profitability

See full
Gross margin79.8%—
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001819790-26-000038
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from maturities of marketable securities74,05591,218
Purchases of marketable securities(126,799)(125,570)
Purchases of property and equipment(5,818)(590)
Net cash used in investing activities(58,562)(34,942)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock, net of paid issuance costs—135,125
Proceeds from exercise of stock options1,2041,437
Net cash provided by financing activities1,204136,562

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s investing cash flow?
Tarsus Pharmaceuticals, Inc. (TARS) reported investing cash flow of -$58.56M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s investing cash flow changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s investing cash flow decreased by 67.6% year-over-year, from -$34.94M to -$58.56M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s investing cash flow?
Over 3 years (2021 to 2024), Tarsus Pharmaceuticals, Inc.'s investing cash flow has grown at a 601.5% compound annual growth rate (CAGR), from -$586K to -$202.32M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude